Share on StockTwits

BioMarin Pharmaceutical (NASDAQ:BMRN) EVP Henry J. Fuchs unloaded 10,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $67.70, for a total value of $677,000.00. Following the completion of the transaction, the executive vice president now directly owns 42,350 shares of the company’s stock, valued at approximately $2,867,095. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of BioMarin Pharmaceutical (NASDAQ:BMRN) traded up 1.16% on Tuesday, hitting $67.96. 525,403 shares of the company’s stock traded hands. BioMarin Pharmaceutical has a 52 week low of $53.14 and a 52 week high of $80.67. The stock’s 50-day moving average is $69.82 and its 200-day moving average is $68.2. The company’s market cap is $9.665 billion.

BMRN has been the subject of a number of recent research reports. Analysts at Deutsche Bank raised their price target on shares of BioMarin Pharmaceutical from $75.00 to $85.00 in a research note to investors on Tuesday, January 14th. They now have a “buy” rating on the stock. Separately, analysts at Barclays downgraded shares of BioMarin Pharmaceutical from an “overweight” rating to an “equal weight” rating in a research note to investors on Friday, January 10th. They now have a $73.00 price target on the stock, down previously from $75.00. Finally, analysts at Nomura initiated coverage on shares of BioMarin Pharmaceutical in a research note to investors on Wednesday, January 8th. They set a “neutral” rating and a $75.00 price target on the stock. Nine equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. BioMarin Pharmaceutical has a consensus rating of “Buy” and an average price target of $77.50.

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) develops and commercializes pharmaceuticals for serious diseases and medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.